CCR4 is an important target for mycosis fungoides (MF) and Sézary syndrome (SS)1-3
CCR4 receptors are highly expressed on the surface of malignant T-cells in all patients with MF and SS, regardless of stage or skin and blood involvement.
POTELIGEO is a nonchemotherapeutic biologic therapy that uniquely targets CCR4+ T cells for destruction via antibody-dependent cellular cytotoxicity (ADCC)4-6
POTELIGEO is a humanized mAb that depletes malignant T cells by targeting CCR4 and enhancing ADCC.4
Learn more about how POTELIGEO targets CCR4+ T cellsView the POTELIGEO and the CCR4 Target video
In the MAVORIC trial, although CCR4 testing was not a requirement for inclusion4:
CCR4=C-C chemokine receptor type 4; mAb=monoclonal antibody
Progression-free survival (PFS) was the primary endpoint measured in the MAVORIC Trial4See efficacy data
- Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405-1410.
- Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol. 2003;48(1):23-30.
- Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol. 2003;121(5):1045-1052.
- POTELIGEO [package insert]. Kyowa Kirin Inc., Bedminster, NJ USA.
- Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2004;10(22):7529-7539.
- Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171-174.